and Ref-1 acts as a reductive activator of many transcription factors in controlling different cellular process such as apoptosis, inflammation, proliferation, angiogenesis, and is involved in survival pathways.
3)4) There are many reports that alterations in the expression, subcellular localization, and activities of APE1/Ref-1 are associated with various human diseases, including cancer, neurodegenerative disease, and hypertension. [4] [5] [6] Because DNA damage plays an important role in the pathogenesis of CAD, [7] [8] [9] alterations 
Subjects and Methods

Study population
This study was approved by the Chungnam National University Hospital Institutional Review Board. We enrolled patients who underwent coronary angiograms (CAG) at the department of cardiology of the Chungnam National University and had signed informed consent forms between January 2012 and May 2013. The patients were classified as controls, consisting of individuals with no significant coronary artery stenosis, or patients with coronary artery disease. The CAD group, with chest pain caused by significant coronary artery stenosis, included stable, unstable angina, and acute myocardial infarction (AMI; Non-ST elevation myocardial infarction, NSTEMI and ST elevation myocardial infarction, STEMI). STEMI was diagnosed when patients came to the hospital with chest pain lasting for more than 30 minutes within the past 12 hours and showing an ST segment elevation of ≥1 mm in more than two adjacent limb leads or ≥2 mm in more than two contiguous precordial leads. NSTEMI was diagnosed in patients with an elevation of cardiac biomarkers and chest pain lasting more than 10 minutes and without evidence of ST segment elevation. CAG in NSTEMI was conducted within 72 hours of admission. Exclusion criteria included controls who had prior CAD or any infectious disorders that caused chest pain, such as pneumonia, cholecystitis, or gastrointestinal disorders. Also, patients with cancer or neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease (known to be associated with an elevated APE1/ Ref-1) were excluded from both the control and CAD groups.
Serum apurinic/apyrimidinic endonuclease 1/redox effector factor 1 measurement All blood samples were taken into vacuum tubes before the CAG.
Serum was separated by centrifugation at 3000 rpm for 10 minutes at room temperature and then re-centrifuged at 5000 rpm for 5 minutes to obtain cell-free serum, which was stored in liquid nitrogen until use. A sandwich enzyme-linked immunosorbent assay (ELISA) was used to quantify serum APE1/Ref-1 levels. Briefly, 96-microwell plates (Nunc) were pre-coated overnight with 100 μL of a 1:1000 dilution of a rabbit anti-APE1/Ref-1 antibody (Abcam, Cambridge, UK) in coating buffer (0.5 M carbonate buffer, pH 9.6) in each well. After blocking with a blocking buffer {5% bovine serum albumin in phosphate buffered saline containing 0.05% Tween 20, (PBS-T)} at room temperature for 60 minutes, 100 μL of sample was added to the wells and the plates were incubated at 4°C for 90 minutes, and then washed 5 times with PBS-T. This was followed by the addition of 100 μL of a 1:1000 dilution of mouse anti-APE1/Ref-1 antibody (Abcam, Cambridge, UK), and further incubation at room temperature for 2 hours. The plate was then washed 7 times with PBS-T, and 100 μL of horseradish peroxidase-conjugated secondary antibody (1:5000) was added, followed by incubation at room temperature for 30 minutes. After further washing, 100 μL of freshly prepared tetramethylbenzidine substrate was added to the wells. The color development reaction was stopped by adding 100 μL of 2.5 M H 2 SO 4 , and the absorbance was measured at 450 nm using an automatic microtiter plate reader (Sunrise Xfluor4; Tecan Systems, Inc., San Jose, CA, USA). Each sample was assayed in duplicate, and mean values were determined. Purified recombinant human APE1/Ref-1 (1 mg/mL) was serially diluted (5-fold) and used in a concentration series from 0.16-20 ng/100 μL to establish a standard curve.
Clinical data collection and clinical outcomes
Basic demographic data, past clinical history, and blood chemistry test results were collected from the patients' medical records. N-terminal pro-B type natriuretic peptide (NT pro-BNP), high sensitivity C-reactive protein (hsCRP), creatinine kinase (CK), CK-MB, and troponin-I were analyzed together.
Patients were monitored for an additional 24.0±7.4 months to determine the occurrence of major adverse clinical events (MACEs). MACEs included death, recurrence of myocardial infarction (MI), stroke, and revascularization including new vessel revascularization, target vessel revascularization, and target lesion revascularization. The revascularization that was planned at the time of enrollment was excluded, and it was only included when it was performed due to the progression of symptoms or stenosis. All events were determined by reviewing the patients' medical records with regular clinical follow-up. In patients without regular clinical follow-up, telephone interviews were conducted and deaths were checked from the nationwide database from the National Health Institute Service in Korea.
Statistical analysis
The data were analyzed using standard software (SPSS version 20.0, IBM Co., Chicago, IL, USA 
Results
Patient characteristics
We enrolled 360 patients in total (237 men; mean age 64±12 years old). The patients included 57 controls (15.8%) and 303 CAD patients (84.2%), including angina (n=128, 35.6%; stable angina, n=52, 14.4%; unstable angina, n=76, 21.1%) and MI (n=175, 48.6%; NSTEMI, n=55, 15.3%; STEMI, n=120, 33.3%). The patients' clinical characteristics are presented in Table 1 . After CAG, percutaneous coronary intervention was performed at the physician's discretion.
Serum apurinic/apyrimidinic endonuclease 1/redox effector factor 1 is elevated in coronary artery disease patients
The serum levels of APE1/Ref-1 in patients with CAD were significantly elevated compared to those of the control group (0.63±0.07 for the CAD group vs. 0.12±0.07 ng/100 μL for the control group, p<0.01) (Fig. 1A ). There were no gender differences (0.59 ±0.08 ng/100 μL for men vs. 0.47±0.10 ng/100 μL for women). The same results were observed in both groups (control vs. CAD; 0.19±0.13 ng/100 μL vs. 0.64±0.89 ng/100 μL for men, 0.07 ±0.06 ng/100 μL vs. 0.60±0.13 ng/100 μL for women, p<0.02). The receiver operating characteristic (ROC) curve analysis was used to evaluate the sensitivity and specificity of APE1/Ref-1 in detecting CAD. The ROC curve from serum samples of 57 controls and 303 patients with CAD resulted in an area under the curve (AUC) of 0.66 (95% confidence interval, 0.592 to 0.729) (Fig. 1B) . The sensitivity and specificity of APE1/Ref-1 were estimated at the optimal cut-off value in order to maximize sensitivity, specificity, and likelihood ratio. On this basis, the optimal combination of sensitivity and specificity were determined to be 0.36 and 0.95, using a cut-off value of 0.16 ng/100 μL. 
is higher in patients with myocardial infarction than angina
The levels of APE1/Ref-1 were higher in patients with MI than angina in the CAD group (0.81±0.101.30 for MI vs. 0.38±0.11 ng/100 μL for angina, p<0.01) (Fig. 2A ). There were not significantly different between NSTEMI and STEMI (0.64±0.12 for NSTEMI vs. 0.89±0.13 ng/100 μL for STEMI, p>0.05). There were significantly higher in STEMI than in the control group, but not in NSTEMI (Fig. 2B) . Also, we analyzed the levels of serum APE1/Ref-1 according to the thrombolysis in myocardial infarction (TIMI) grade flow in patients with acute coronary syndrome (ACS), including unstable angina, NSTEMI, and STEMI. The lower TIMI flow was significantly correlated with higher APE1/Ref-1 (0.12±0.07 for control vs. 0.45±0.13 for TIMI flow 3 vs. 0.88±0.09 ng/100 μL for TIMI flow 0-2, p<0.01) (Fig. 2C) . Four days after the CAG, serum APE1/Ref-1 was re-measured from 37 patients who were selected randomly among the STEMI patients. The levels of the biomarker declined from 1.62±0.27 ng/100 μL to 0.35±0.23 ng/100 μL (Fig.  2D) . positively correlated with serum APE1/Ref-1 (r=0.217, p<0.01 for NT pro-BNP, and r=0.222, p<0.01 for troponin I) ( Fig. 3A and B) . There was no significant correlation with hsCRP (Fig. 3C ). The ejection fraction, which is known to be associated with prognosis, was negatively correlated with serum APE1/Ref-1 (r=-0.221, p<0.01) (Fig.  3D) . Neither peak troponin I nor peak CK-MB had a significant correlation.
Relationship of serum apurinic
Impact of serum apurinic/apyrimidinic endonuclease 1/redox effector factor 1 on adverse clinical events
No MACEs were observed in the control group during the followup period. There were 35 MACEs in the CAD group during the follow-up of 24.0±7.4 months, including 26 deaths, 1 stroke, and 8 revascularizations. The incidence was not different between the angina and MI groups (total MACE 9.4% for angina vs. 13.1% for MI; p>0.05) ( Table 2) . We compared MACEs among three groups divided by serum APE1/Ref-1 concentrations; <0.10, >0.10 and <1.10, and >1.10. There were no significant differences between the three groups ( Table 2) . Cox proportional hazard regression also showed that serum APE1/Ref-1 was not associated with MACE. Only hsCRP appeared to be associated with MACE (hazard ratio 1.029, p<0.01), but not NT-proBNP or ejection fraction.
Discussion
In this report, we demonstrate, for the first time, that serum APE1/Ref-1 is increased in patients with coronary artery disease, and that it is correlated with NT pro-BNP, troponin I and ejection fraction. The cut-off value of APE1/Ref1 to distinguish the CAD group from the control group is 0.16 ng/100 μL, providing the optimal combination of sensitivity, specificity, and likelihood ratio. clinical outcomes, such as NT-proBNP, high troponin I, and ejection fraction, with the exception of hsCRP, were not associated with MACEs. That means the sample size of this study was too small to confirm these effects. Also, the fact that MI patients have a worse prognosis compared with angina was not seen in the present study. So, we think that a larger study is needed to evaluate the relationship between serum APE1/Ref-1 and clinical outcomes and to determine its usefulness for prognosis. Our study has several limitations related to its small sample size. Although we included blood samples from all groups we examined, all measurements of serum APE1/Ref-1 were not taken at the same time and within six months after the initial collection. Even though we excluded diseases such as cancer, Alzheimer's disease and Parkinson's disease, we could not completely eliminate other possible conditions that could cause changes in APE1/Ref-1. The possibility that medication could be responsible for alterations of APE1/Ref-1 should be considered, even though we followed the protocol for drug therapies.
In conclusion, we found that serum APE1/Ref-1 may be increased in patients with CAD. It is correlated with other cardiovascular biomarkers such as troponin I, N-terminal pro-B type and ejection fraction. However, we need larger studies to determine its usefulness as a novel biomarker for the early diagnosis and prognostic prediction in CAD.
